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Abstract
Background: Advanced glycation end products (AGEs) have been proposed to be involved in
pulmonary fibrosis, but its role in this process has not been fully understood. To investigate the
role of AGE formation in pulmonary fibrosis, we used a bleomycin (BLM)-stimulated rat model
treated with aminoguanidine (AG), a crosslink inhibitor of AGE formation.
Methods: Rats were intratracheally instilled with BLM (5 mg/kg) and orally administered with AG
(40, 80, 120 mg/kg) once daily for two weeks. AGEs level in lung tissue was determined by ELISA
and pulmonary fibrosis was evaluated by Ashcroft score and hydroxyproline assay. The expression
of heat shock protein 47 (HSP47), a collagen specific molecular chaperone, was measured with RT-
PCR and Western blot. Moreover, TGFb1 and its downstream Smad proteins were analyzed by
Western blot.
Results: AGEs level in rat lungs, as well as lung hydroxyproline content and Ashcroft score, was
significantly enhanced by BLM stimulation, which was abrogated by AG treatment. BLM significantly
increased the expression of HSP47 mRNA and protein in lung tissues, and AG treatment markedly
decreased BLM-induced HSP47 expression in a dose-dependent manner (p < 0.05). In addition, AG
dose-dependently downregulated BLM-stimulated overexpressions of TGFb1, phosphorylated (p)-
Smad2 and p-Smad3 protein in lung tissues.
Conclusion: These findings suggest AGE formation may participate in the process of BLM-induced
pulmonary fibrosis, and blockade of AGE formation by AG treatment attenuates BLM-induced
pulmonary fibrosis in rats, which is implicated in inhibition of HSP47 expression and TGFb/Smads
signaling.
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Background
Pulmonary fibrosis is a devastating disorder and no effec-
tive treatment is available now. Although the underlying
molecular mechanisms of pulmonary fibrosis remain not
fully understood, increased synthesis and deposition of
extracellular matrix (ECM) is confirmed to be an impor-
tant pathological feature of pulmonary fibrosis [1].
Advanced glycation end products (AGEs), the irreversible
products of nonenzymatic glycation of proteins, nucleic
acids and lipids, are increased in situations with hypergly-
cemia and oxidative stress, which involves a series of com-
plex biochemical events with oxidative and nonoxidative
molecular rearrangements [2,3]. Previous studies have
suggested that AGEs have multiple potential effects on
various disorders [2-4]. T Matsuse et al reported AGE
modified proteins accumulated in alveolar macrophages
in patients with idiopathic pulmonary fibrosis [5], which
suggests for the first time that AGEs probably contribute
to the pathogenesis of pulmonary fibrosis. However, its
role in pulmonary fibrosis has not been well-elucidated.
So far, several investigators have documented AGEs can
induce ECM excessive deposition and expression of heat
shock protein (HSP) 47 and profibrotic cytokines, such as
transforming growth factor b (TGFb) 1  [ 6 ] .  H S P 4 7 ,  a
stress-inducible protein localized in the endoplasmic
reticulum, is determined to play a specific role in the intra-
cellular processing, folding, assembly and secretion of
procollagens as a collagen molecular chaperone [7,8].
HSP47 expression is often prominent during the process
of fibrosis in both humans and animal models [9-12]. In
lung fibrosis, the HSP47-positive cells are considered to
be the main source of collagen synthesis [9,13], which
suggests a potentially important role of HSP47 in the
pathogenesis of pulmonary fibrosis. TGFb is a member of
a large superfamily of pleiotropic cytokines which are
involved in many biological activities, including cell pro-
liferation, differentiation, migration and apoptosis [14].
Moreover, TGFb, especially the isoform TGFb1, is a key
fibrotic stimulator in pulmonary fibrosis [15]. Generally,
TGFb performs its profibrotic effects via cascade stimula-
tion of downstream intracellular Smad proteins. Among
these Smads, Smad2 and Smad3 are necessary for TGFb
signal transduction [14,15]. Bleomycin (BLM), an antitu-
mor drug, is often used to establish rodent models to
mimic the pathologic features of idiopathic pulmonary
fibrosis (IPF). Intratracheal instillation of bleomycin,
induces pulmonary fibrosis following a gross inflamma-
tion in airways, which means a inflammatory and fibrotic
phase is included in the process of BLM-induced lung
injury. Time course studies have indicated the switch
between the inflammatory and fibrotic phases is around
day 9 after BLM treatment [16], and day 14 may be a more
suitable time point for assessing lung fibrosis, considering
the extensive fibrosis, but less variability in the fibrotic
response and lower mortality than later time points [17].
Based on these points mentioned above, we used a rat
model of pulmonary fibrosis stimulated by BLM instilla-
tion, treated with aminoguanidine (AG), an inhibitor of
AGE formation by carbonyl-blocking [2], to explore
whether AGE formation participates in BLM-induced pul-
monary fibrosis, and whether it is involved in HSP47
expression and TGFb signaling pathway.
Methods
Animals and Reagents
Pathogen free male Sprague-Dawley rats (250–300 g)
were purchased from Experimental Animal Center of
Sichuan University. Bleomycin was purchased from Har-
bin Bolai Pharmaceutical Co. Ltd (Harbin, China) and
aminoguanidine was bought from Sigma (St. Louis, MO,
USA).
Treatment of Animals
This animal study was approved by the Panel on Labora-
tory Animal Care of West China School of Medicine,
Sichuan University. These animals were housed in the
temperature (22 ± 2°C) – and humidity (60 ± 5%)-con-
trolled condition and kept on a 12-h light/dark cycle, with
24-h free access to the standard Purina (5001) rodent
chow (autoclaved) and tap water that was heated to boil-
ing for 20 min and then cooled to the room temperature
before using it. Thirty rats were randomly divided into six
experimental groups, with five rats per group, as follows:
1) Saline (SA)-treated with distilled water (DW) (SA
group); 2) BLM-treated with DW (BLM group); 3) BLM-
treated with AG (40, 80, 120 mg/kg) (BLM plus AG
group); 4) SA-treated with AG (120 mg/kg) (AG group).
Rats were anesthetized intraperitoneally with chloral
hydrate (3 ml/kg) [18] and bleomycin (5 mg/kg) in 100
ml of saline was administered by intratracheal instillation
with the same volume of saline in control animals. AG
was dissolved in DW at a dose of 8 mg/ml. AG or DW was
administered by gavage once daily from day 1 to day 14
after BLM or saline treatment (day 0) and all rats were sac-
rificed with exsanguination on day 15 (Figure 1).
Bleomycin administration and treatment protocol Figure 1
Bleomycin administration and treatment protocol. 
BLM instillation was performed on day 0. Following this, AG 
was administered by gavage from day 1 to day 14. All rats 
were killed on day 15.Respiratory Research 2009, 10:55 http://respiratory-research.com/content/10/1/55
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Histopathology
Middle lobes of right lungs were embedded in paraffin,
following fixation in 10% buffering formalin, and then
processed to obtain 4-mm sections for Masson's trichrome
staining. Histopathologic evaluation of pulmonary fibro-
sis was performed using Ashcroft scoring method. Briefly,
the grade of lung fibrosis was scored on a scale of 0 to 8
using the following criteria: grade 0, normal lung; grade 1
to 2, minimal fibrous thickening of alveolar or bronchi-
olar wall; grade 3 to 4, moderate thickening of walls with-
out obvious damage to lung architecture; grade 5 to 6,
increased fibrosis with definite damage to lung structure;
grade 7 to 8; severe distortion of structure and large
fibrous areas [19]. After the examination of 30 randomly
chosen regions in each sample at a magnification of ×100,
the mean score of all the fields was taken as the fibrosis
score in each sample. The scoring method strictly fol-
lowed the blind principle.
Hydroxyproline Assay
To assess collagen accumulation, lung tissues (40 mg per
rat lung, wet weight) were used for measurement of
hydroxyproline content. Hydroxyproline assay was per-
formed according to the instruction of hydroxyproline test
kit from Nanjing Jiancheng Bioengineering Institute
(Nanjing, China). In brief, frozen lung tissues were
homogenized by a Polytron tissue homogenizer in saline
containing 0.1 M phenylmethylsulfonylfluoride. The
homogenized sample was hydrolyzed in 6 N HCl, and the
hydroxyproline concentration was determined according
to the method of Otsuka et al [20].
RT-PCR
For RNA isolation, lung tissues were frozen in liquid nitro-
gen and stored in -80°C freezer immediately. Total RNA
was extracted from frozen lung tissues (left lungs) using
Trizol reagent (Gibco-BRL, Gaithersburg, MD, USA), and
amplified using a PCR single-step kit (Promega, USA),
according to the manufacturer's instructions. RT-PCR was
performed with PTC-200 DNA Engine PCR cycler (MJ
Research, Inc., USA). The primers, which were designed
based on published sequence of these genes and synthe-
sized by Invitrogen (Carlsbad, CA), as follows: HSP47,
forward (5'-CAAGAA CA AG GC AG AC TTATCGC-3');
reverse (5'-TCTGAT T AT CTCGCACCAGGAAG-3'), b-
actin, forward (5'-C C T C A TGAAGATCCTGACCG-3');
reverse (5'-ACCGCTCA TTGCCG ATA G TG-3'). b-actin
served as the constitutive control. The annealing tempera-
ture for each primer pair was 59°C to HSP47 and 58°C to
b-actin, respectively. The products were separated by aga-
rose gel electrophoresis and visualized by Gelview
(Bioteke Corporation, Beijing, China). Semiquantitative
densitometric analysis was performed with the Bio-Rad
Universal Hood and Bio-Rad Quantity One software (Bio-
Rad, Hercules, CA). Means of the ratio of HSP47 band
photodensity to b-actin band photodensity in various
groups were presented.
ELISA
Lung tissues for ELISA were homogenized in 10 mM Tris
buffer (pH 7.4) containing 1% Triton X-100, 1 mM EDTA,
1 mM PMSF, 10 ug/ml aprotinin, and 10 ug/ml leupeptin.
Protein concentration was quantitated by the Bicin-
choninic Acid (BCA) Method according to the instruction
of the BCA protein assay kit (Pierce, Rockford, IL). AGEs
level in lung tissues was determined according to the
instruction of the commercial ELISA kit (Uscnlife, Mis-
souri City, TX). Samples were measured photometrically
by an automated plate reader (Microplate Reader Model
1680; Bio-Rad, USA).
Western Blot
Lung homogenates were prepared in lysis buffer, contain-
ing 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 2 mM NaF, 2 mM EDTA, 0.1% SDS
and a protease inhibitor cocktail tablet (Roche Applied
Science, Indianapolis, IN, USA). Protein concentration
was quantitated by BCA Method described above. Equal
amounts of protein samples (30 mg) from each group were
loaded onto each lane of gels. Samples and prestained
molecular weight markers (Bio-Rad, Hercules, CA) were
subsequently electrophoresed on 12% Tris-glycine poly-
acrylamide gels and then were electrophoretically trans-
ferred onto polyvinylidene difluoride (PVDF) membranes
(Millipore Corp., Marlborough, MA). The membranes
were blocked for 1 h at room temperature with 5% Bovine
Serum Albumin (BSA) and were incubated overnight at
4°C with primary antibodies including anti-HSP47
(Santa Cruz), anti-TGFb1 (Cell Signaling), anti-Smad2
(Cell Signaling), anti-Smad3 (Cell Signaling), anti-p-
Smad2 (Cell Signaling), anti-p-Smad3 (Cell Signaling),
and anti-b-actin (Santa Cruz), at a dilution of 1:1000 in
Tris-buffered saline with Tween-20 (TBST). b-actin served
as the constitutive control to confirm equal amounts of
protein loading. After washing with TBST, the membranes
were incubated with the corresponding horseradish per-
oxidase-linked antirabbit antibody (Pierce, Rockford, IL)
diluted 1:20000 in TBST for 1 h at room temperature.
After further washing with TBST, immunoreactive bands
were visualized by enhanced chemiluminescence (ECL),
and quantified by densitometry with the Bio-Rad Univer-
sal Hood and Quantity One software (Bio-Rad). All
results were normalized to b-actin levels in each lane.
Statistical Analysis
All values were expressed as means ± standard deviation
(SD). One-way ANOVA followed by Student-Newman-
Keuls test was used to compare the differences among
multiple groups. Significance was defined by a P value ofRespiratory Research 2009, 10:55 http://respiratory-research.com/content/10/1/55
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0.05. SPSS 13.0 software package (SPSS, Inc., Chicago, IL)
was used for statistical analysis.
Results
AGEs level as well as bleomycin-induced pulmonary 
fibrosis is attenuated by AG treatment
Bleomycin instillation significantly induced pulmonary
fibrosis (Figure 2A). Compared with the SA group, AGEs
level in lung tissues was markedly increased in the BLM
group (p < 0.01; Figure 2B), and was dose-dependently
decreased with AG treatment, similar to the changes of
Ashcroft score and lung hydroxyproline content (Figure
2C, D), which were used for assessing the degree of pul-
monary fibrosis. Masson staining of lung specimens dem-
onstrated that bleomycin instillation induced severe
distortion of lung structure and accumulation of collagen
fiber (blue) in rat lungs, whereas a well-alveolized normal
histology was seen in rats treated with saline (Figure 2A).
The histopathological characteristics of the SA group were
not significantly different from those of the AG group. AG
treatment significantly attenuated bleomycin-induced
fibrotic lesions and collagen fiber accumulation in rat
lungs in a dose-dependent manner. To confirm the effect
of AG on the histopathological change of bleomycin-
induced pulmonary fibrosis, the overall grades of the
fibrotic changes of the lungs were performed by Ashcroft
Effect of AG on AGEs level and bleomycin-induced pulmonary fibrosis Figure 2
Effect of AG on AGEs level and bleomycin-induced pulmonary fibrosis. (A) Shown are representative photomicro-
graphs of Masson-stained sections of lung tissues from each group. Collagens were stained blue. Bar = 100 mm. Comparisons of 
AGEs level (B), Ashcroft score (C) and lung hydroxyproline content (D) among different experimental groups were presented. 
Data represent mean ± SD, n = 5 in each group,* p < 0.01 vs SA group; † p < 0.05 vs BLM group; ‡ p < 0.01 vs BLM group.Respiratory Research 2009, 10:55 http://respiratory-research.com/content/10/1/55
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score (Figure 2C). The score of the BLM+AG group was
significantly lower than that of the BLM group (p < 0.01).
Collagen deposition in lung tissues was assessed by meas-
uring the hydroxyproline content. Compared with the SA
group, hydroxyproline content was significantly increased
in the BLM group after bleomycin infusion. The increased
hydroxyproline content in rat lungs was decreased dose-
dependently with AG administration (p < 0.05; Figure
2D). However, no significant differences were observed in
levels of AGEs, Ashcroft score, and lung hydroxyproline
content between the SA and AG groups.
HSP47 mRNA and protein overexpressions in lung tissues 
induced by bleomycin are inhibited by AG treatment
HSP47 mRNA expression in rat lungs was measured by
RT-PCR. The expression of HSP47 mRNA in the BLM
group was much higher than control rats in the SA group
(p < 0.01). AG treatment significantly inhibited BLM-
induced HSP47 mRNA expression in lung tissues (p <
0.05, p < 0.01; Figure 3). This inhibitory effect was in a
dose-dependent manner. Meanwhile, BLM stimulation
significantly increased HSP47 protein expression in rat
lungs (p < 0.01), which was inhibited by AG treatment
dose-dependently (p < 0.05, p < 0.01; Figure 4A, B). These
changes in the Western blot were in accordance with the
findings in the RT-PCR study. No significant changes of
HSP47 mRNA and protein were revealed in the SA and AG
groups.
TGFb1, p-Smad2, p-Smad3 protein expressions in lung 
tissues after bleomycin stimulation are downregulated by 
AG treatment
As a key factor of pulmonary fibrosis, TGFb1 was deter-
mined by Western blot. BLM significantly increased
TGFb1 protein expression in lung tissues (p < 0.01),
which was downregulated by AG treatment dose-depend-
ently (p < 0.01; Figure 4A, C). No significant difference
was revealed in TGFb1 expression level between the SA
and AG groups.
Because phosphorylation of Smad signaling by the acti-
vated TGFb1 receptor I is a major step in the initiation of
TGFb1 signal transduction, we further examined whether
Smad2 and Smad3 phosphorylation in bleomycin-
induced pulmonary fibrosis was changed by AG treat-
ment. Immunoblot analysis showed a marked increase in
Smad2 and Smad3 phosphorylation in the BLM lungs
over the SA lungs after bleomycin treatment (p < 0.01).
AG administration dose-dependently reduced the phos-
phorylation of Smad2 and Smad3 protein in the bleomy-
cin-induced pulmonary fibrosis (p < 0.05, p < 0.01; Figure
4A, D, E). However, there were no significant changes in
total Smad2 and Smad3 expressions among experimental
groups (Figure 4A), and no significant differences were
observed in Smad2 and Smad3 phosphorylation between
the SA group and AG group.
Discussion
In the present study, BLM stimulation markedly increased
the level of AGEs in lung tissues as well as lung hydroxy-
proline content and fibrosis score, which were inhibited
with treatment of AG, an AGE formation inhibitor, in a
dose-dependent manner. Further, AG treatment also
decreased BLM-induced HSP47 expression, downregu-
lated TGFb1, p-Smad2 and p-Smad3 expressions, and
subsequently attenuated BLM-induced pulmonary fibro-
sis. From these findings, we conclude that AGEs may play
an important role in pulmonary fibrosis induced by BLM,
which may be involved in its potentially regulatory effects
on HSP47 expression and TGFb/Smads signaling path-
way.
Prior studies have strongly evidenced the positive roles of
AGEs in the process of fibrogenesis. Huang et al and Lee
et al reported AGE dose- and time-dependently increased
Effect of AG on bleomycin-induced HSP47 mRNA expres- sion Figure 3
Effect of AG on bleomycin-induced HSP47 mRNA 
expression. The expression of HSP47 mRNA was measured 
by RT-PCR. The mean ratios of photodensity of HSP47 band 
to that of b-actin control were shown. Data represent mean 
± SD, n = 5 in each group,* p < 0.01 vs SA group; † p < 0.05 
vs BLM group; ‡ p < 0.01 vs BLM group.Respiratory Research 2009, 10:55 http://respiratory-research.com/content/10/1/55
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collagen production and connective tissue growth factor
(CTGF) mRNA and protein expression in NRK-49F (nor-
mal rat kidney fibroblast) cells [21,22]. In human foreskin
fibroblasts, Lohwasser et al found AGE incubation could
increase CTGF, TGF-b1, and procollagen-alpha1 (I)
mRNA [23]. Futher more, AGE treatment significantly
increased fibronectin and type IV collagen accumulation
in renal glomeruli, and also markedly induced renal TGF-
b1 and CTGF expression in rats [24]. These in-vitro and in-
vivo experimental studies indicate AGEs could be an effec-
tive stimulator in fibrogenesis. In the present study, our
data confirm AGEs accumulation is paralleled with the
progression of BLM-induced pulmonary fibrosis assessed
by lung hydroxyproline assay and fibrotic scoring, and
blockade of AGE formation by AG treatment significantly
attenuates BLM-induced pulmonary fibrosis, which sup-
ports the participation of AGE formation in this process.
As excessive deposition of ECM may contribute to pulmo-
nary fibrosis [1] and collagens are the major fibrous pro-
teins in ECM, we considered AGEs could have effects on
collagen synthesis within the process of pulmonary fibro-
sis. HSP47, as a specific collagen molecular chaperone,
was reported to be correlated well with collagen deposi-
tion in both animal and human studies [25-27], which
suggests an important role of HSP47 in increased deposi-
tion of collagens during the progression of fibrotic dis-
eases. Moreover, recent researches by Hagiwara and his
colleagues reported that inhibition of HSP47 by antisense
oligodeoxynucleotides significantly suppressed the pro-
duction of collagen and subsequently attenuated pulo-
monary fibrosis in bleomycin-, lipopolysaccharide- and
paraquat-induced pulmonary fibrosis in rats [28-30].
These findings further demonstrate a key role of HSP47 in
collagen synthesis during the course of pulmonary fibro-
sis. The present results show overexpression of HSP47
induced by BLM is dose-dependently inhibited by AG
treatment, which indicates that AGE formation may par-
ticipate in BLM-stimulated pulmonary fibrosis at least
partly through upregulation of HSP47 expression, and
HSP47 may be a critical target factor of AGEs in BLM-
induced pulmonary fibrosis. But so far very little is known
about the underlying molecular mechanism by which
AGE formation modulates HSP47 expression in BLM-
stimulated pulmonary fibrosis.
It has been well-documented that TGFb1 appears to be the
predominant isoform of TGFbs involved in pulmonary
fibrosis, which exerts its profibrotic effects through chem-
oattraction and stimulation of fibroblasts to express
growth factors and extracellular matrix components [8].
Several reporters demonstrated TGFb1, as a major regula-
tor, stimulated HSP47 expression, in parallel with colla-
gen production [26,31-33]. Simultaneously, as was also
Effect of AG on HSP47, TGFb1, p-Smad2, Smad2, p-Smad3 and Smad3 protein after bleomycin instillation Figure 4
Effect of AG on HSP47, TGFb1, p-Smad2, Smad2, p-Smad3 and Smad3 protein after bleomycin instillation. 
Western blot was performed to determine the expression levels of target proteins. (A) Representative blotting images of 
HSP47, TGFb1, p-Smad2, Smad2, p-Smad3, Smad3, and b-actin were shown. Densitometric analysis of HSP47 (B), TGFb1 (C), 
p-Smad2 (D), p-Smad3 (E) protein expression relative to the b-actin control was presented. Data represent mean ± SD, n = 5 
in each group, * p < 0.01 vs SA group; † p < 0.05 vs BLM group; ‡ p < 0.01 vs BLM group.Respiratory Research 2009, 10:55 http://respiratory-research.com/content/10/1/55
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reported, AGEs could increase both TGFb1 and HSP47
expression in cultured mesangial cells [6]. Although there
are no direct evidences to determine whether TGFb signal-
ing contributes to AGE induction of HSP47 expression, Li
and his colleagues reported AGE induced a rapid Smad2
and Smad3 nuclear translocation and phosphorylation by
normal rat tubular epithelial cells, glomerular mesangial
cells, and vascular smooth muscle cells in a dose- and
time-dependent manner, which was mediated by TGFb
signaling pathway [34], and Ohashi et al further found
mesangial cells transfected with Smad1-antisense oligom-
ers showed much less expression of HSP47 and type IV
collagen transcripts after AGE stimulation than those with
control oligomers [6]. These studies indicate TGFb/smads
might play an important role in the process of AGE-
induced HSP47 expression. So, we hypothesised the
potentially regulatory effect of AGEs on BLM-induced
HSP47 expression was involved in TGFb/smads pathway.
In our study, through inhibition of AGE formation in
BLM-induced lung fibrosis by AG treatment, the expres-
sions of TGFb1, p-Smad2 and p-Smad3 were all downreg-
ulated dose-dependently, suggesting TGFb/Smads
signaling pathway probably plays a role in AGE-regulated
HSP47 expression induced by BLM, although this link still
needs more evidences to confirm.
Taken together, our results demonstrate AGE formation
contributes to BLM-stimulated lung fibrosis, and HSP47
may be a potential target factor of AGEs. Blockade of AGE
formatioin by AG treatment attenuates BLM-induced
HSP47 overexpression, probably through inhibition of
TGFb1/Smad2/Smad3 signaling pathway, which suggests
for the first time that AGEs may participate in the process
of BLM-induced pulmonary fibrosis, at least partly impli-
cated in TGFb/Smads-HSP47 pathway. The further study
should focus on whether the contribution of AGEs to the
lung fibrosis is involved in its receptor, the receptor of
AGEs (RAGE). In recent studies, loss of RAGE was
observed in the lungs of IPF patients and bleomycin- or
asbestos-treated rats [35,36]. In addition, RAGE-null mice
developed more severe pulmonary fibrosis than wild-type
controls [35], indicative of a protective role of RAGE in
lung fibrosis. However, He et al demonstrated that RAGE
contributed to bleomycin-induced lung fibrosis through
epithelial-mesenchymal transition and profibrotic
cytokine production [37]. It can be seen the role of RAGE
in pulmonary fibrosis needs further determination.
Conclusion
AGEs are complex products of nonenzymatic glycation,
with links to fibrotic lesions in various disorders. Our
findings firstly demonstrate AGE formation may partici-
pate in BLM-induced pulmonary fibrosis, and TGFb/
Smads-HSP47 pathway is probably implicated in this
process, although more investigations are needed to con-
firm this mechanism. Moreover, the inhibitory effect of
AG on HSP47 expression and TGFb/smads signaling path-
way in BLM-induced pulmonary fibrosis, is supposed to
be a beneficial supplement for more understanding of the
protective role of AG in BLM-induced pulmonary fibrosis.
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